Last Updated On 9/28/2023 10:21:17 AM
This is a disclosure report of the user financial relationships with for-profit health care companies.
All relationships are considered compensated unless otherwise noted. Relationships are self-held unless otherwise noted.
Employment |
No Relationships to Disclose |
|
|
Leadership |
No Relationships to Disclose |
|
|
Stock and Other Ownership Interests |
No Relationships to Disclose |
|
|
Honoraria |
No Relationships to Disclose |
|
|
Consulting or Advisory Role |
Company: Metys Pharmaceuticals |
Recipient: You |
Company: DISARM Pharmaceuticals |
Recipient: You |
Company: Onquality |
Recipient: You |
Company: NKMax |
Recipient: You |
Company: Mitsubishi Tanabe Pharma |
Recipient: You |
Company: Veloxis |
Recipient: You |
Company: Metys Pharmaceuticals |
Recipient: You |
Company: Hengrui Pharmaceutical |
Recipient: You |
Company: Osmol Therapeutics |
Recipient: You |
Company: Gruenthal |
Recipient: You |
Company: Neuropathix |
Recipient: You |
Company: Denali Therapeutics |
Recipient: You |
Company: Bexion |
Recipient: You |
Company: Veloxis |
Recipient: You |
Company: Vevro |
Recipient: You |
Company: Galendia |
Recipient: You |
Company: Hengrui Pharmaceuticals |
Recipient: You |
Company: Neuropathix |
Recipient: You |
Company: Neuropathix |
Recipient: You |
Company: Denali Therapeutics |
Recipient: You |
Company: Bexion |
Recipient: You |
Company: Bexion |
Recipient: You |
Company: Bexion |
Recipient: You |
Company: Genentech |
Recipient: You |
|
Speakers' Bureau |
No Relationships to Disclose |
|
|
Research Funding |
Company: Bristol-Myers Squibb |
Recipient: Your Institution |
|
Patents, Royalties, Other Intellectual Property |
No Relationships to Disclose |
|
|
Expert Testimony |
No Relationships to Disclose |
|
|
Travel, Accommodations, Expenses |
No Relationships to Disclose |
|
|
Other Relationship |
No Relationships to Disclose |
|
|
(OPTIONAL) Uncompensated Relationships |
No Relationships to Disclose |
|
|
(OPTIONAL) Open Payments Link |
not answered |
|
|